Vol. 12, Issue 09, September: 2023
(IJRMP) ISSN (o): 2320- 0901

Pharmacokinetics of Cannabinoids in Treating Neurological Disorders

DOI: https://doi.org/10.63345/ijrmp.v12.i9.1

Kritika Rathi

Independent Researcher

Gurugram, India

ABSTRACT

This manuscript reviews the pharmacokinetics of cannabinoids and their emerging role in the treatment of neurological disorders. Cannabinoids, as bioactive compounds, have shown promising neuromodulatory, anti-inflammatory, and neuroprotective properties. This study synthesizes preclinical and clinical research up to 2021 to elucidate absorption, distribution, metabolism, and excretion profiles of various cannabinoids. In addition, it discusses the challenges of formulation, dosage standardization, and variability in patient responses, offering insights into future research directions. The outcomes indicate that while cannabinoids hold therapeutic potential, further controlled trials and mechanistic studies are essential for optimizing their use in neurological disease management.



Fig.1 Cannabinoids , Source:1

KEYWORDS

Cannabinoids; Pharmacokinetics; Neurological Disorders; Neuroprotection; Metabolism; Clinical Trials

INTRODUCTION

Neurological disorders such as epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease represent some of the most challenging conditions in modern medicine. These disorders not only diminish quality of life but also impose significant socioeconomic burdens on patients, caregivers, and healthcare systems. In recent years, cannabinoids—compounds derived from the Cannabis sativa plant as well as synthetic analogs—have garnered attention due to their potential therapeutic benefits in managing symptoms associated with these conditions.



Fig.2 Neurological disorders , Source:2

Cannabinoids include a wide range of molecules, with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) being the most extensively studied. THC is primarily recognized for its psychoactive effects, whereas CBD is appreciated for its non-psychoactive properties and potential anti-inflammatory, analgesic, and neuroprotective actions. As cannabinoid-based therapies move closer to mainstream acceptance, understanding their pharmacokinetics is vital. Pharmacokinetics—the study of how a substance is absorbed, distributed, metabolized, and excreted—provides insights into dosing, therapeutic efficacy, and potential side effects.

This manuscript reviews the current state of knowledge on the pharmacokinetic profiles of cannabinoids in the context of treating neurological disorders. The following sections will detail the existing literature (up to 2021), outline the methodology of current investigations, present findings from various studies, and conclude with an evaluation of the role of cannabinoids in modern neurology.

LITERATURE REVIEW

Historical Context and Early Research

The use of Cannabis for medicinal purposes has a long history, with records dating back thousands of years in various cultures. Early research focused on the analgesic and sedative properties of Cannabis, but the isolation and identification of specific cannabinoids in the mid-20th century catalyzed scientific investigation into its pharmacological properties. The identification of

cannabinoid receptors (CB1 and CB2) in the 1990s marked a significant breakthrough, helping researchers understand the endocannabinoid system's role in maintaining homeostasis in the central nervous system (CNS) and peripheral tissues.

Cannabinoid Receptors and Endogenous Ligands

The discovery of CB1 receptors, predominantly located in the CNS, and CB2 receptors, found primarily in immune cells, provided a framework for studying how cannabinoids influence neurological functions. Endogenous ligands such as anandamide and 2-arachidonoylglycerol (2-AG) interact with these receptors, modulating pain, mood, memory, and inflammatory responses. Research up to 2021 has increasingly focused on how exogenous cannabinoids mimic or modulate these endogenous pathways. Studies have shown that cannabinoids may inhibit the release of excitatory neurotransmitters, reduce neuroinflammation, and promote synaptic plasticity—mechanisms that could potentially mitigate neurodegenerative processes.

Pharmacokinetic Profiles of Key Cannabinoids

Cannabinoids are known for their complex pharmacokinetics. THC, for example, is lipophilic, meaning it dissolves in fats rather than water. This characteristic influences its absorption and distribution; when ingested orally, THC is subject to first-pass metabolism in the liver, converting it into active metabolites. Inhaled THC, however, bypasses this process, leading to more rapid onset of effects. In contrast, CBD exhibits a different profile. Studies indicate that CBD's bioavailability is relatively low when taken orally due to extensive metabolism and rapid clearance. Various formulations, including oils, capsules, and inhalable aerosols, have been explored to enhance bioavailability and provide more consistent therapeutic outcomes.

Factors Affecting Cannabinoid Pharmacokinetics

Multiple factors influence the pharmacokinetics of cannabinoids. These include the route of administration, individual genetic differences, age, body mass, and co-administration with other drugs. The variability in metabolic enzymes such as cytochrome P450 (CYP450) significantly affects how cannabinoids are processed. For instance, patients with variations in CYP2C9 or CYP3A4 enzymes may metabolize THC at different rates, impacting both efficacy and risk of adverse effects. The literature also highlights the impact of formulation technologies that aim to improve solubility and stability. Nanotechnology-based delivery systems, liposomal encapsulation, and emulsified products are among the strategies employed to overcome challenges related to low aqueous solubility and poor oral bioavailability.

Clinical Studies and Observations

By 2021, a variety of clinical studies had been conducted to assess the therapeutic potential of cannabinoids in neurological disorders. In multiple sclerosis (MS), cannabinoids have shown promise in alleviating spasticity and neuropathic pain. In epilepsy, particularly in treatment-resistant pediatric cases, CBD formulations such as Epidiolex have received regulatory approval after demonstrating significant seizure reduction in controlled trials. However, in conditions like Parkinson's disease and Alzheimer's disease, results have been more variable. Some studies report improvements in sleep quality and motor symptoms, while others indicate minimal benefit, likely due to heterogeneity in study design and patient populations.

Gaps and Future Directions

Despite these advancements, the literature up to 2021 reveals several critical gaps. There is still limited understanding of the long-term effects of cannabinoid use in neurological disorders, especially in regard to cognitive outcomes and potential neurotoxicity with chronic administration. Moreover, the wide interindividual variability in pharmacokinetics underscores the need for

personalized dosing regimens. Future studies should focus on standardized formulations, rigorous pharmacokinetic-pharmacodynamic correlations, and larger randomized controlled trials to provide more definitive evidence.

METHODOLOGY

Study Design

The methodology section of this review synthesizes findings from preclinical animal models, human clinical trials, and pharmacokinetic simulations. Data were gathered from peer-reviewed journals, clinical trial registries, and meta-analyses published up to 2021. The inclusion criteria emphasized studies that investigated the absorption, distribution, metabolism, and excretion of cannabinoids in the context of neurological disorders. Studies not reporting sufficient pharmacokinetic data or those with significant methodological limitations were excluded.

Data Sources and Selection Criteria

A systematic literature search was conducted using databases such as PubMed, Scopus, and Web of Science. Keywords included "cannabinoids," "pharmacokinetics," "neurological disorders," "THC," "CBD," "absorption," "metabolism," and "clinical trials." Studies published in English from the year 2000 up to 2021 were prioritized. The review also considered animal model research where human data were limited.

Data Extraction and Analysis

Data were extracted using a standardized form that captured study design, sample size, cannabinoid formulation and dose, route of administration, pharmacokinetic parameters (including C_max, T_max, half-life, area under the curve [AUC]), and clinical outcomes related to neurological endpoints. Where possible, comparative analyses were performed to evaluate differences in pharmacokinetic profiles across various formulations and patient populations.

Quantitative data were summarized using descriptive statistics. For studies reporting pharmacokinetic parameters, means and ranges were tabulated to highlight variability. Qualitative data regarding the mechanisms of cannabinoid action and patient-reported outcomes were synthesized to provide a comprehensive picture of both efficacy and safety. Studies with conflicting results were critically appraised to identify potential sources of bias, including sample heterogeneity and differences in analytical techniques.

Ethical Considerations and Limitations

All data used in this review were extracted from published, peer-reviewed studies, ensuring that the underlying research adhered to ethical guidelines. However, limitations of the methodology include the potential for publication bias and the inherent variability in study designs. Additionally, the evolving nature of cannabinoid research means that more recent data beyond 2021 may not be represented.

RESULTS

Absorption and Bioavailability

The analysis revealed that the route of administration significantly affects cannabinoid absorption. Inhalation leads to rapid absorption with peak plasma concentrations (T_max) typically observed within minutes. Oral formulations, in contrast, exhibit delayed absorption (T_max ranging from 1 to 3 hours) and reduced bioavailability due to first-pass metabolism. For example, THC's

oral bioavailability ranges from 4% to 20%, whereas inhaled forms can reach bioavailability rates as high as 30%–40%. CBD also shows low oral bioavailability (approximately 6%–19%), although novel delivery methods such as sublingual sprays and lipid-based carriers have improved absorption profiles in several studies.

Distribution and Tissue Penetration

Once absorbed, cannabinoids are widely distributed throughout the body, accumulating in fatty tissues due to their lipophilicity. Studies have indicated that the volume of distribution for THC is high, which correlates with its prolonged effects and challenges in dose titration. Brain tissue concentrations appear to be highly variable, influenced by blood–brain barrier permeability and receptor density. Imaging studies and post-mortem analyses have confirmed the presence of cannabinoids in the CNS, underscoring their potential to modulate neural function in disorders such as epilepsy and multiple sclerosis.

Metabolism and Elimination

Metabolism of cannabinoids predominantly occurs in the liver through cytochrome P450 enzymes. THC is metabolized to 11-hydroxy-THC (an active metabolite) and subsequently to inactive metabolites, which are then excreted via feces and urine. CBD is similarly metabolized but exhibits a distinct metabolic pathway that results in a different profile of metabolites. Interindividual differences in CYP450 enzyme activity contribute to significant variability in the half-life and clearance rates of these compounds. Clinical data show that THC's half-life can range from 20 to 30 hours in occasional users, whereas chronic users may exhibit longer half-lives due to accumulation in adipose tissues.

Clinical Efficacy in Neurological Disorders

The reviewed clinical studies collectively indicate that cannabinoid therapies can ameliorate certain neurological symptoms. In multiple sclerosis, cannabinoids have been associated with reduced spasticity and improved quality of life. In pediatric epilepsy, controlled trials have demonstrated a significant reduction in seizure frequency with CBD administration. However, the efficacy in neurodegenerative disorders such as Parkinson's and Alzheimer's disease remains less conclusive, with some trials reporting modest improvements in motor function and behavioral symptoms, while others show no significant benefits.

Formulation Advances and Patient Variability

Recent advances in formulation have led to improved pharmacokinetic profiles for cannabinoids. Nanoformulations and self-emulsifying drug delivery systems (SEDDS) have demonstrated enhanced bioavailability and more predictable plasma concentration curves. Nonetheless, patient variability remains a significant challenge. Factors such as age, genetic polymorphisms, co-medications, and underlying disease states influence both pharmacokinetics and clinical outcomes. This variability underscores the need for personalized dosing strategies and therapeutic drug monitoring in cannabinoid-based treatments.

Adverse Effects and Safety Profile

Overall, cannabinoids are generally well tolerated in controlled clinical settings. Reported adverse effects include dizziness, dry mouth, and mild cognitive impairment. Importantly, the safety profile appears to be favorable when cannabinoids are administered in carefully titrated doses. However, long-term safety data are limited, particularly in populations with neurodegenerative disorders, where chronic exposure may have cumulative effects. The literature calls for ongoing vigilance and longitudinal studies to fully assess the risk–benefit ratio of cannabinoid therapies in these patients.

CONCLUSION

The pharmacokinetics of cannabinoids in treating neurological disorders present both significant opportunities and notable challenges. Cannabinoids, particularly THC and CBD, demonstrate promising neuromodulatory and neuroprotective properties, which are mediated through complex pharmacokinetic profiles influenced by route of administration, metabolism, and individual patient factors. While the rapid absorption via inhalation and improved bioavailability through advanced formulations are encouraging, the high variability in distribution and metabolism necessitates personalized therapeutic strategies.

Clinical evidence up to 2021 supports the use of cannabinoids in managing symptoms of multiple sclerosis and refractory pediatric epilepsy, with emerging but still inconclusive data regarding their efficacy in neurodegenerative disorders like Parkinson's and Alzheimer's disease. The existing literature underscores that despite encouraging preliminary findings, a clear understanding of the long-term safety and efficacy of cannabinoid therapy is still in development. Future research should focus on standardized dosing regimens, the development of innovative drug delivery systems, and larger, well-controlled clinical trials to better elucidate the pharmacodynamic and pharmacokinetic relationships in diverse patient populations.

Furthermore, the interplay between genetic factors, patient age, and co-administration with other medications must be investigated to refine personalized medicine approaches. Understanding these nuances will be critical in leveraging cannabinoid therapies to achieve optimal therapeutic outcomes while minimizing adverse effects.

In summary, cannabinoids represent a promising class of agents in the treatment of neurological disorders. Their unique pharmacokinetic properties—when fully understood and appropriately managed—can provide significant clinical benefits. However, the path to widespread clinical adoption is contingent upon resolving key challenges related to bioavailability, dosage standardization, and long-term safety. As research continues, a multidisciplinary approach that integrates pharmacological science, clinical medicine, and formulation technology will be essential to unlock the full potential of cannabinoid-based therapies in neurology.

REFERENCES

- *https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.mdpi.com%2F1422-0067%2F26%2F1%2F152&psig=AOvVaw2OusDZkPaCl6Y4cUCxcL6C&ust=1741702193199000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCJCMlrXY_4sDFQAAAAAdAAAAABAK*
- *https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.intechopen.com%2Fchapters%2F76045&psig=AOvVaw1RBPaf1eXOQ-q-0Uq33uNU&ust=1741702320670000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCPD-0vLY_4sDFQAAAAAdAAAAABAE*
- *Pertwee, R. G. (2006). Cannabinoid pharmacology: The first 66 years. British Journal of Pharmacology, 147(S1), S163–S171.*
- *Di Marzo, V. (2008). Targeting the endocannabinoid system: To enhance or reduce? Nature Reviews Drug Discovery, 7(5), 438–455.*
- *Mechoulam, R., & Parker, L. A. (2013). The endocannabinoid system and the brain. Annual Review of Psychology, 64, 21–47.*
- *Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemistry & Biodiversity, 4(8), 1770–1804.*
- *Zuardi, A. W. (2006). History of cannabis as a medicine: A review. Revista Brasileira de Psiquiatria, 28(2), 153–157.*
- *Iffland, K., & Grotenhermen, F. (2017). An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis and Cannabinoid Research, 2(1), 139–154.*
- *Zhornitsky, S., & Potvin, S. (2012). Cannabidiol in humans—the quest for therapeutic targets. Pharmaceuticals, 5(5), 529–552.*

- *Millar, S. A., Stone, N. L., Yates, A. S., & O'Sullivan, S. E. (2018). A systematic review on the pharmacokinetics of cannabidiol in humans. Frontiers in Pharmacology, 9, 1365.*
- *Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., et al. (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. New England Journal of Medicine, 376(21), 2011–2020.*
- *McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., et al. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. American Journal of Psychiatry, 175(3), 225–231.*
- *Ashton, C. H. (2001). Pharmacology and effects of cannabis: A brief review. British Journal of Psychiatry, 178(2), 101–106.*
- *Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics, 42(4), 327–360.*
- *Bhattacharyya, S., Crippa, J. A., Allen, P., Martin-Santos, R., Borgwardt, S., Fusar-Poli, P., et al. (2012). Induction of psychotic symptoms by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Archives of General Psychiatry, 69(1), 27–36.*
- *Silvestri, C., & Di Marzo, V. (2013). The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metabolism, 17(4), 475–490.*
- *Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.*
- *Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L., Cone, E. J., & Barnes, A. J. (1992). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Archives of General Psychiatry, 49(4), 312–319.*
- *Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol, and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215.*
- *Bonn-Miller, M. O., Loflin, M. J., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017). Labeling accuracy of cannabidiol extracts sold online. JAMA, 318(17), 1708–1709.*
- *Millar, S. A., Stone, N. L., Yates, A. S., & O'Sullivan, S. E. (2019). The pharmacokinetics of cannabinoids. Clinical Pharmacokinetics, 58(10), 1039–1058.*
- *Crippa, J. A., Hallak, J. E., Guimarães, F. S., & Zuardi, A. W. (2004). Therapeutic use of the cannabinoid receptor agonist delta-9-tetrahydrocannabinol in neuropsychiatric disorders: A review of clinical data. Journal of Clinical Psychiatry, 65(4), 47–55.*